ZyVersa Therapeutics (ZVSA) Competitors

3.9% of ZyVersa Therapeutics shares are held by institutional investors. Comparatively, 36.0% of Flora Growth shares are held by institutional investors. 0.2% of ZyVersa Therapeutics shares are held by insiders. Comparatively, 2.3% of Flora Growth shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

ZyVersa Therapeutics has higher earnings, but lower revenue than Flora Growth. ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.

Flora Growth has a consensus target price of $30.00, suggesting a potential upside of 503.62%. Given Flora Growth's stronger consensus rating and higher possible upside, analysts plainly believe Flora Growth is more favorable than ZyVersa Therapeutics.

In the previous week, ZyVersa Therapeutics and ZyVersa Therapeutics both had 1 articles in the media. Flora Growth's average media sentiment score of 0.84 beat ZyVersa Therapeutics' score of 0.00 indicating that Flora Growth is being referred to more favorably in the news media.

ZyVersa Therapeutics has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. Flora Growth's return on equity of -64.02% beat ZyVersa Therapeutics' return on equity.

ZyVersa Therapeutics has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, Flora Growth has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500.

5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are owned by institutional investors. 30.7% of Akari Therapeutics shares are owned by insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Akari Therapeutics presently has a consensus target price of $89.00, suggesting a potential upside of 1,483.63%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Akari Therapeutics is more favorable than ZyVersa Therapeutics.

In the previous week, Akari Therapeutics and Akari Therapeutics both had 1 articles in the media. Akari Therapeutics' average media sentiment score of 0.00 equaled ZyVersa Therapeutics'average media sentiment score.

Akari Therapeutics' return on equity of -70.34% beat ZyVersa Therapeutics' return on equity.

Akari Therapeutics has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, ZyVersa Therapeutics has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.

11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are owned by institutional investors. 20.3% of Acurx Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than ZyVersa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Acurx Pharmaceuticals presently has a consensus target price of $31.00, suggesting a potential upside of 1,450.00%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Acurx Pharmaceuticals is more favorable than ZyVersa Therapeutics.

In the previous week, Acurx Pharmaceuticals had 1 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 2 mentions for Acurx Pharmaceuticals and 1 mentions for ZyVersa Therapeutics. Acurx Pharmaceuticals' average media sentiment score of 0.00 equaled ZyVersa Therapeutics'average media sentiment score.

ZyVersa Therapeutics' return on equity of -109.54% beat Acurx Pharmaceuticals' return on equity.

Acurx Pharmaceuticals has a beta of -2.09, suggesting that its share price is 309% less volatile than the S&P 500. Comparatively, ZyVersa Therapeutics has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.

Biodexa Pharmaceuticals has higher revenue and earnings than ZyVersa Therapeutics.

Biodexa Pharmaceuticals has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, ZyVersa Therapeutics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.

In the previous week, ZyVersa Therapeutics had 1 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 1 mentions for ZyVersa Therapeutics and 0 mentions for Biodexa Pharmaceuticals. Biodexa Pharmaceuticals' average media sentiment score of 0.00 equaled ZyVersa Therapeutics'average media sentiment score.

17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are owned by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are owned by company insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Biodexa Pharmaceuticals' return on equity of 0.00% beat ZyVersa Therapeutics' return on equity.